hotspot -WSS

hotspot

author：leisure time 2025-10-02 23:32:04 - browse：29

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Medicare Advantage today, explained in one chart

WSS

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The tragedy of Johnson & Johnson’s Covid vaccine

The surgeon had a dilemma only a Nazi medical text could resolve

Prior authorization will have to move faster under new Biden rule

Dewpoint Therapeutics lays off staff after losing partnerships

Biotech venture capitalists face new demands from investors

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

BioMarin wins approval for gene therapy to treat hemophilia A

There’s no way to know how good AI health technologies are

Guidelines to prevent youth baseball injuries need more muscle

FDA clears AI tool for detecting skin cancer

Anesthesiologist group: stop taking Ozempic before surgery

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Tori Bowie and the unacceptable rates of Black maternal death

There’s no way to know how good AI health technologies are

Virginia high school admissions case could be legal follow

Test for long Covid? Researchers find new clue in blood samples

focus

European regulators consider appeal over Amylyx ALS drug

Eli Lilly, Pfizer, and others want in on the online prescription market

Female surgeons have lower rates of long

How clinical AI models' predictive power can degrade over time

Cancer cells are shown to suck energy source from immune cells

Readout LOUD podcast: Merger Mondays, Ozempic panic

knowledge

hotspot

focus

focus